We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates.
- Authors
Al Kaabi, Nawal; Oulhaj, Abderrahim; Ganesan, Subhashini; Al Hosani, Farida Ismail; Najim, Omer; Ibrahim, Halah; Acuna, Juan; Alsuwaidi, Ahmed R.; Kamour, Ashraf M.; Alzaabi, Ashraf; Al Shehhi, Badreyya Ahmed; Al Safar, Habiba; Hussein, Salah Eldin; Abdalla, Jehad Saleh; Al Mansoori, Dalal Saeed Naser; Al Hammadi, Ahmed Abdul Kareem; Amari, Mohammed A.; Al Romaithi, Ahmed Khamis; Weber, Stefan; Elavalli, Santosh
- Abstract
The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes. There is limited real-world evidence for the effectiveness of the BBIBP-CorV (Sinopharm) vaccine against severe COVID-19 disease. Here, the authors use data from Abu Dhabi and estimate effectiveness at 80% against hospitalization; 86% against critical care admission and 84% against death.
- Subjects
ABU Dhabi (United Arab Emirates); VACCINE effectiveness; COVID-19; BOOSTER vaccines; ELECTRONIC health records; PROPORTIONAL hazards models; VACCINATION
- Publication
Nature Communications, 2022, Vol 13, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-022-30835-1